Art. -Nr.: HY-W014841

Sodium hippurate, 98%

(Synonyms: N-Benzoylglycine sodium, 98%)

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

Sodium hippurate, 98% is an orally active metabolite. Sodium hippurate, 98% can be produced by intestinal microorganisms from the metabolism of polyphenols, benzoic acid. Sodium hippurate, 98% decreases NRF2, MMP9 and leads to ROS accumulation. Sodium hippurate, 98% activates TGFβ/SMAD signaling. Sodium hippurate, 98% improves hyperuricemia and colitis. Sodium hippurate, 98% can also be used in cardiovascular disease research. .

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.91%
CAS. Nr.: 532-94-5
Formel: C₉H₈NNaO₃
Molecular Weight:201.16

Speicherung:

Store at room temperature, keep dry and cool.

In solvent -80°C, 1 year , -20°C, 6 months

Sodium hippurate, 98% Chemical Structure

CAS. Nr.: 532-94-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]^[2]^[3]^[4]. ^[5]^[6]^[7]^[8]^[9]

MMP9

Microbial Metabolite

Human Endogenous Metabolite

Alle MMP Isoform-spezifische Produkte anzeigen :

Alle TGF-beta/Smad Isoform-spezifische Produkte anzeigen :

Smad1
Smad3

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

In Vitro

Sodium hippurate, 98% (Hippuric acid, 25 μM; 24 h) co-incubated with Dexamethasone (HY-14648) significantly increases C2C12 myotube diameter, abrogates dexamethasone-induced reductions in myotube protein synthesis rates, and partially attenuates the increase in proteolysis in C2C12 myotubes under atrophy-like conditions^[2].
Sodium hippurate, 98% (Hippuric acid, 1-2 mM; 15 min) significantly reduces P-selectin/CD62P expression and inhibits PAC-1 activation-dependant antibody expression in platelets stimulated ex vivo via the P₂Y₁/P₂Y₁₂-adenosine diphosphate (ADP) pathway^[3].
Sodium hippurate, 98% (Hippuric acid, 0-1000 μM; 24 h) increases fibrosis-related gene expression, extracellular matrix imbalance, and oxidative stress in HK-2 cells^[4].
Sodium hippurate, 98% (Hippuric acid, 200-400 ng/mL; 24 h) increases ABCG2 expression and apical localization in Caco-2 cells^[5].
Sodium hippurate, 98% (Hippuric acid, 8 mg/mL; 24 h) decreases pro-inflammatory cytokine production and promotes the expression of ZO-1 in NCM460 cells treated with dextran sulfate sodium^[6].
Sodium hippurate, 98% (Hippuric acid, concentration equivalent to that in 2.5% serum from blueberry-diet-fed rats) inhibits osteoclastogenesis and osteoclast resorptive activity in nonadherent mouse bone marrow cells isolated from 4-week-old C57BL6/J mice^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[4]

Cell Line:

HK-2 cells
Concentration:

0 μM, 62.5 μM, 125 μM, 250 μM, 500 μM, 1000 μM
Incubation Time:

24 h
Result:

Increased COL1A1, VIM, and ACTA2 protein levels, and reduced CDH1 levels in a concentration-dependent manner.
Attenuated MMP9 protein levels, while increasing TIMP1 levels.
Activated TGFβ/SMAD signaling, and the fibrotic responses were mediated by ROS activation of this pathway.
Inhibited the antioxidant pathway by downregulating NRF2 protein, as shown by reduced protein expression of NRF2 and its downstream antioxidant enzymes (HO1 and NQO1).

In Vivo

Sodium hippurate, 98% (Hippuric acid, 100 mg/kg; i.p.; five times per week; 10 weeks) promotes renal fibrosis and dysfunction in 5/6 nephrectomized rats^[4].
Sodium hippurate, 98% (Hippuric acid, 10 mg/kg; p.o.; daily; 4 weeks) alleviates hyperuricemia in mice by promoting intestinal urate excretion via enhancing ABCG2-mediated transport^[5].
Sodium hippurate, 98% (Hippuric acid, 50-150 mg/kg; p.o.; once daily; 7 days) alleviates DSS-induced colitis in male C57BL/6J mice, as shown by reduced clinical activity, improved intestinal barrier integrity, and modulated gut microbiota^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Sprague Dawley rats (7-week-old, weight not specified); 5/6 nephrectomy model^[4]
Dosage:

100 mg/kg
Administration:

Intraperitoneal injection, five times per week, for 10 weeks
Result:

Significantly increased levels of serum creatinine (SCr), blood urea nitrogen (BUN), and HA.
Showed increased tubulointerstitial fibrosis and glomerulosclerosis, with larger COL1A1-, VIM-, and ACTA2-positive areas.
Revealed lower NRF2 levels.
Decreased activities of SOD, CAT, and GSH- Px.
Increased MDA levels in the kidneys, indicating redox imbalance.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 532-94-5
Appearance Solid
Molecular Weight 201.16
Formel C₉H₈NNaO₃
Color White to off-white
SMILES

O=C(CNC(C1=CC=CC=C1)=O)O[Na]
Synonyms

N-Benzoylglycine sodium, 98%
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Store at room temperature, keep dry and cool

In solvent	-80°C	1 year
	-20°C	6 months

Publications (2)

All

Sort by:

Journal Impact Factor

Drug Des Devel Ther

Gut-Derived Hippuric Acid Alleviates Hepatic Lipid Metabolism via UGDH/FOXK1/CD36 Axis in Obese Mice. [Abstract]

2026 Mar 3:20:595588. PMID: 41800297
Biomedicines

Hippuric Acid Suppresses Triple-Negative Breast Cancer via the EGFL8-Notch Signaling Axis. [Abstract]

2026 Jun 21;14(6):1400. PMID: 42351828

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 33.33 mg/mL (165.69 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.9712 mL

24.8558 mL

49.7117 mL

5 mM

0.9942 mL

4.9712 mL

9.9423 mL

10 mM

0.4971 mL

2.4856 mL

4.9712 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Bergmeyer H U, et al. Biochemical reagents[M]//Methods of Enzymatic Analysis. Academic Press, 1965: 967-1037.

[2]. Edwards SJ, et al. (-)-Epicatechin and its colonic metabolite hippuric acid protect against dexamethasone-induced atrophy in skeletal muscle cells. J Nutr Biochem. 2022 Dec;110:109150. [Content Brief]

[3]. Santhakumar AB, et al. The ex vivo antiplatelet activation potential of fruit phenolic metabolite hippuric acid. Food Funct. 2015 Aug;6(8):2679-83. [Content Brief]

[4]. Sun B, et al. Hippuric Acid Promotes Renal Fibrosis by Disrupting Redox Homeostasis via Facilitation of NRF2-KEAP1-CUL3 Interactions in Chronic Kidney Disease. Antioxidants (Basel). 2020 Aug 25;9(9):783. [Content Brief]

[5]. Xu YX, et al. Alistipes indistinctus-derived hippuric acid promotes intestinal urate excretion to alleviate hyperuricemia. Cell Host Microbe. 2024 Mar 13;32(3):366-381.e9. [Content Brief]

[6]. Yang Y, et al. Hippuric acid alleviates dextran sulfate sodium-induced colitis via suppressing inflammatory activity and modulating gut microbiota. Biochem Biophys Res Commun. 2024 May 28;710:149879. [Content Brief]

[7]. Zhao H, et al. Hippuric acid and 3-(3-hydroxyphenyl) propionic acid inhibit murine osteoclastogenesis through RANKL-RANK independent pathway. J Cell Physiol. 2020 Jan;235(1):599-610. [Content Brief]

[8]. Griffith W H. Inhibition of tissue respiration by sodium benzoate and sodium hippurate. Proceedings of the Society for Experimental Biology and Medicine, 1937, 37(2): 279-280.

[9]. Chen JR, et al. GPR109A mediates the effects of hippuric acid on regulating osteoclastogenesis and bone resorption in mice. Commun Biol. 2021 Jan 8;4(1):53. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.9712 mL	24.8558 mL	49.7117 mL	124.2792 mL
	5 mM	0.9942 mL	4.9712 mL	9.9423 mL	24.8558 mL
	10 mM	0.4971 mL	2.4856 mL	4.9712 mL	12.4279 mL
	15 mM	0.3314 mL	1.6571 mL	3.3141 mL	8.2853 mL
	20 mM	0.2486 mL	1.2428 mL	2.4856 mL	6.2140 mL
	25 mM	0.1988 mL	0.9942 mL	1.9885 mL	4.9712 mL
	30 mM	0.1657 mL	0.8285 mL	1.6571 mL	4.1426 mL
	40 mM	0.1243 mL	0.6214 mL	1.2428 mL	3.1070 mL
	50 mM	0.0994 mL	0.4971 mL	0.9942 mL	2.4856 mL
	60 mM	0.0829 mL	0.4143 mL	0.8285 mL	2.0713 mL
	80 mM	0.0621 mL	0.3107 mL	0.6214 mL	1.5535 mL
	100 mM	0.0497 mL	0.2486 mL	0.4971 mL	1.2428 mL

Keywords

Sodium hippurate, 98%

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Sodium hippurate, 98%

Anti-Fibrosis Compound Library

Non-natural Amino Acid Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Endogenous Metabolite Library

Anti-Rheumatic Arthritis Compound Library

Lactylation Compound Library

Drug Fragment Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

TGF-beta/Smad Compound Library

Wnt/Hedgehog/Notch Compound Library

Clinical Compound Library

Human Endogenous Metabolite Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Ferroptosis Compound Library

Orally Active Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Microbial Metabolite Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Pain-Related Compound Library

Protease Inhibitor Library

Animal-Sourced Natural Product Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Sodium hippurate, 98%

Alle MMP Isoform-spezifische Produkte anzeigen

Alle TGF-beta/Smad Isoform-spezifische Produkte anzeigen

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Sodium hippurate, 98% Related Classifications

HY-W014841 Related Classifications